Navigation Links
A novel target for therapeutics against Staph infection
Date:11/27/2008

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease. Their work appears November 28 in the open-access journal PLoS Pathogens.

Once occurring more commonly in healthcare facilities, but now affecting segments of the general population, MRSA is a bacterial pathogen responsible for a range of diseases from mild skin infection to life-threatening sepsis. Even with antibiotics, these infections can still be fatal.

Senior author Magnus Hk, Ph.D. and his colleagues carried out biochemical and structural studies to determine the binding mechanism of clumping factor A (ClfA), a surface protein that plays an important role in the pathogenesis of S. aureus. The group found that ClfA binds to the blood-clotting protein fibrinogen (Fg) at a site that is also responsible for inducing platelet activation and thrombosis (clot inside a blood vessel).

The results show significant structural differences in how staphylococcal and platelet receptor proteins recognize fibrinogen. By exploiting this difference in recognition, the researchers show that agents could be designed that inhibit the ClfAFg interaction but do not interfere with the interaction of Fg with the platelet integrin, therefore avoiding unwanted side effects on the circulatory system.


'/>"/>

Contact: Mary Kohut
Press@plos.org
415-568-3457
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Corn researchers discover novel gene shut-off mechanisms
2. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
3. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
4. GEN reports on novel tools for deciphering biological networks
5. Novel publishing approach puts textbook in more hands
6. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
7. Childrens National researchers develop novel anti-tumor vaccine
8. LIAI launches new division to look at novel approaches to heart disease and inflammation
9. Conaway Lab identifies novel mechanism for regulation of gene expression
10. Scientists identify novel inhibitor of human microRNA
11. Using novel tool, UD researchers dig through cell trash and find treasure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology: